Inhaled medicines beyond asthma and COPD Part 1
Part 1/3 Unmet needs – poorly treated lung diseases
Sweden has been a strong player in the field of inhaled medicines for several decades. Today, a range of efficacious medicines are available for asthma and COPD, among others developed by AstraZeneca. This series of three seminars initiates the discussion around other, poorly treated lung diseases. This first one presents diseases and patient groups, location of targets in the lungs and some of the challenges around accessing the medical targets.
The seminar series is organized by the Swedish Inhalation Network, SwedIN, in collaboration with Apotekarsocieteten, section for drug formulation and is intended for everyone who has an interest in the pharmaceutics and bio-pharm of lung delivery.
With Anna-Karin Larsson Callerfelt, Lunds Universitet och Markus Fridén, AstraZeneca.
Moderator: Kyrre Thalberg, senior Advisor at Emmace Consulting AB and Adjunct Professor at Lund University
Time and place
Last day to register is 10th of March